Welcome!

Video Authors: Elizabeth White, Yakov Fain, Liz McMillan, Dan Ristic, Jnan Dash

News Feed Item

MDA Names Dr. Grace Pavlath to Head Scientific Program as Research Department Intensifies Focus on Ushering Treatments Through Drug Pipeline

CHICAGO, Sept. 25, 2014 /PRNewswire-USNewswire/ -- Dr. Grace Pavlath, an accomplished muscle disease researcher and tenured professor in the Department of Pharmacology at the Emory University School of Medicine, has been named as MDA Senior Vice President – Scientific Program Director. Beginning October 31, Dr. Pavlath will become a key member of MDA's Mission Leadership Team and will be responsible for overall management and further development of MDA's scientific program focused on delivering effective therapies for more than 40 neuromuscular diseases and ALS.

MDA logo

"For almost 30 years, Dr. Pavlath has established herself as a leading researcher in cellular and molecular mechanisms that are critical for muscle growth and repair," said Executive Vice President and Chief Medical and Scientific Officer Valerie Cwik, M.D., who will work closely with Pavlath in maintaining the results-driven focus of MDA's program. "She brings a profound understanding and insider's knowledge to today's research landscape and will play a critical role in further leveraging MDA's clinic infrastructure and research programs while working collaboratively with industry stakeholders." 

"Dr. Pavlath's breadth of experience including her deep immersion in neuromuscular research, teaching, mentorship and international scientific leadership roles will serve MDA well as we strengthen our vital commitment to therapy development, which is so critical to MDA's mission to save and improve lives of people fighting muscle disease," said MDA President and CEO Steven M. Derks. "We're thrilled to have someone with Grace's skills join our fight. This is a pivotal time in our history, when we are poised on the brink of new discoveries. Some of our MDA-funded researchers who've been working in the field for decades are so encouraged by the progress being made and the clinical trials underway that they tell us they feel more hopeful than at any other time in their careers."

MDA has redoubled its urgency and commitment to its research program, having adopted strategies that demand a more intentional and proactive perspective on the grant proposal process, with new goals and measurables embedded within the program. MDA plans to direct a greater percentage of its research budget to therapy development. Furthermore, MDA will endeavor to identify key areas to invest research dollars and help identify any gaps in therapy development strategy while proactively requesting grant proposals to fill in those gaps.

"We want more drugs moving through the development pipeline," said Cwik. "The goal is to get them out of the laboratory, through FDA approval and ultimately to individuals affected." MDA is seeking to double the number of drugs being funding annually through its translational research program.

"I am thrilled and honored to join MDA at a time when we are identifying strategies to overturn obstacles in therapy development, actively seeking to accelerate progress for the sake of the children and adults MDA serves," said Pavlath. "I look forward to strengthening my relationships with members of the neuromuscular disease community, so that together we can assess research needs and scientific opportunities that will accelerate and meet MDA's mission objectives."

As MDA's scientific program leader, Pavlath will be based in Atlanta and will provide leadership for MDA through interactions with federal agencies, international neuromuscular disease partners, drug development groups and pharmaceutical companies, as well as with patient advocacy groups and other neuromuscular disease stakeholders while meeting the organization's core standards of excellence. She will also represent MDA at national and international neuromuscular scientific meetings and as an advocate on Capitol Hill in behalf of the families served by MDA.

Pavlath, a graduate of the University of California, Berkeley, received her Ph.D. in Pharmacology from Stanford University and did postdoctoral training at Stanford University and the University of Arizona. She joined Emory University in 1994 as an assistant professor. She is currently a professor in the Department of Pharmacology at Emory.

Pavlath's scientific work has been widely published in peer review journals, and she is the recipient of numerous research grants from the National Institutes of Health, American Heart Association, Emory University, as well as the Muscular Dystrophy Association. She has served and currently serves on numerous national, international and institutional committee memberships, and has organized and chaired several conferences with the focus ranging from skeletal muscle and stem cells to muscle development, function and repair. She has also been a member of the MDA Scientific Advisory Committee since 2008.

About MDA
The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to saving and improving the lives of people with muscle disease, including muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research to find treatments and cures; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement.

Visit mda.org and follow us at facebook.com/MDAnational and @MDAnews. Learn more about MDA's mission by watching this video.

Logo - http://photos.prnewswire.com/prnh/20120424/DC93207LOGO

SOURCE Muscular Dystrophy Association

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
To Really Work for Enterprises, MultiCloud Adoption Requires Far Better and Inclusive Cloud Monitoring and Cost Management … But How? Overwhelmingly, even as enterprises have adopted cloud computing and are expanding to multi-cloud computing, IT leaders remain concerned about how to monitor, manage and control costs across hybrid and multi-cloud deployments. It’s clear that traditional IT monitoring and management approaches, designed after all for on-premises data centers, are falling short in ...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Dynatrace is an application performance management software company with products for the information technology departments and digital business owners of medium and large businesses. Building the Future of Monitoring with Artificial Intelligence. Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more busine...